ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Pharmaxis Cancer Drug Decreases Tumour Burden in Pre Clinical Liver Cancer Model
August 05, 2021Clinical stage drug development company Pharmaxis Ltd today announced the first public presentation of data from a preclinical study of PXS-5505 in the liver cancer, cholangiocarcinoma (CCA) at the Americas Hepato-Pancreato-Biliary Association (AHBPA) ... -
EffRx Signs Agreement with Pharmaxis for Registration, Commercialization of Bronchitol®
June 14, 2019EffRx Pharmaceuticals has entered into an exclusive license agreement with Pharmaxis, a listed pharmaceutical research company in Australia, for the registration and commercialization of Bronchitol® (mannitol) for cystic fibrosis in Switzerland. -
Pharmaxis Announces Resubmission of Bronchitol NDA
December 26, 2018Pharmaceutical research company Pharmaxis (ASX: PXS) today announced the resubmission of the Bronchitol New Drug Application with the United States Food and Drug Administration (FDA) by its licensee Chiesi Group (Chiesi). -
Pharmaxis Releases Positive Results of for LOXL2 Trial
October 12, 2018Pharmaxis announced positive results from the Phase 1 clinical trial for the first of its Lysyl Oxidase Like 2 (LOXL2) inhibitor compounds being developed to treat fibrotic diseases such as Non‐Alcoholic Steatohepatitis (NASH) and Idiopathic Pulmonary Fib
Pharma Sources Insight January 2025
